破发股迪哲医药预计减亏 正拟定增2021年上市募21亿

Core Viewpoint - Dizh Medical (688192.SH) has announced a projected net loss for the year 2024, despite an expected significant increase in revenue compared to the previous year [1][2]. Financial Performance - The company anticipates a revenue of approximately 360 million yuan for 2024, which represents an increase of about 294.35% compared to the previous year [1]. - Research and development expenses are expected to be around 738 million yuan, reflecting a decrease of approximately 8.39% year-on-year [1]. - The projected net loss attributable to the parent company is around 865 million yuan, which is a reduction of about 21.91% compared to the previous year [1]. - The net loss after excluding non-recurring items is expected to be approximately 918 million yuan, also showing a decrease of about 20.91% year-on-year [1]. Historical Context - In 2023, Dizh Medical reported a revenue of approximately 91.29 million yuan and a net loss of 1.108 billion yuan, which was an increase in loss from 736 million yuan in the previous year [2]. - The company has been operating at a net cash flow deficit from operating activities, with a net cash flow of -968 million yuan in 2023, compared to -603 million yuan in the previous year [2]. Stock and Financing Information - Dizh Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, 2021, with an initial issuance of 40 million shares at a price of 52.58 yuan per share [3]. - The stock is currently trading below its initial offering price, indicating a state of "broken issue" [4]. - The total funds raised from the initial public offering amounted to 2.103 billion yuan, with a net amount of 1.987 billion yuan after deducting issuance costs [5]. - The company plans to raise up to 1.848 billion yuan through a private placement of A-shares, which will be used for new drug research and development, international standard innovative drug industrialization projects, and to supplement working capital [7][8]. Shareholding Structure - Dizh Medical has no controlling shareholder or actual controller, with a relatively dispersed shareholding structure [9]. - AstraZeneca AB and Advanced Manufacturing Industry Investment Fund (Limited Partnership) are the largest shareholders, each holding 26.69% of the company's shares as of the reporting period [9].